Compare ULY & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ULY | JAGX |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 3.9M |
| IPO Year | N/A | N/A |
| Metric | ULY | JAGX |
|---|---|---|
| Price | $2.04 | $1.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $11.50 | ★ $60.00 |
| AVG Volume (30 Days) | 68.8K | ★ 387.2K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $127,932,000.00 | $11,785,000.00 |
| Revenue This Year | N/A | $22.41 |
| Revenue Next Year | $18.95 | $30.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.45 |
| 52 Week Low | $1.74 | $1.00 |
| 52 Week High | $17.99 | $33.25 |
| Indicator | ULY | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 42.25 | 41.91 |
| Support Level | $1.85 | $1.05 |
| Resistance Level | $3.13 | $1.36 |
| Average True Range (ATR) | 0.30 | 0.15 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 21.01 | 38.00 |
Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.